Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
09
04
2021
accepted:
03
05
2021
pubmed:
25
9
2021
medline:
13
1
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
Most genetic studies of nonalcoholic fatty liver disease (NAFLD) have been conducted in Whites. In this large and ethnically diverse cohort, we assessed the transportability of previously identified genetic variants for NAFLD, built a genetic risk score (GRS), and examined its association with NAFLD risk in multiple ethnic groups. Thirty previously identified genome-wide association studies (GWAS) variants (P < 5 × 10
Identifiants
pubmed: 34558842
doi: 10.1002/hep4.1751
pmc: PMC8485887
pii: 02009842-202110000-00007
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1689-1703Subventions
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA228589
Pays : United States
Informations de copyright
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis‐new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013;10:627‐636.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73‐84.
Pais R, Barritt AS, Calmus Y, Scatton O, Runge T, Lebray P, et al. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol 2016;65:1245‐1257.
Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851‐859.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123‐133.
Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta‐analysis. Clin Gastroenterol Hepatol 2018;16:198‐210.e192.
Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology 2016;64:1969‐1977.
DiStefano JK, Kingsley C, Craig Wood G, Chu X, Argyropoulos G, Still CD, et al. Genome‐wide analysis of hepatic lipid content in extreme obesity. Acta Diabetol 2015;52:373‐382.
Feitosa MF, Wojczynski MK, North KE, Zhang Q, Province MA, Carr JJ, et al. The ERLIN1‐CHUK‐CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study. Atherosclerosis 2013;228:175‐180.
Parisinos CA, Wilman HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, et al. Genome‐wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol 2020;73:241‐251.
Speliotes EK, Yerges‐Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome‐wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461‐1465.
Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, et al. Genome‐wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011;43:1131‐1138.
Prins BP, Kuchenbaecker KB, Bao Y, Smart M, Zabaneh D, Fatemifar G, et al. Genome‐wide analysis of health‐related biomarkers in the UK Household Longitudinal Study reveals novel associations. Sci Rep 2017;7:11008.
Yuan X, Waterworth D, Perry JRB, Lim N, Song K, Chambers JC, et al. Population‐based genome‐wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008;83:520‐528.
Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, et al. Genome‐wide association study of non‐alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol 2020;73:505‐515.
Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non‐alcoholic fatty liver disease in Japanese. PLoS One 2012;7:e38322.
Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al. Genome‐wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013;132:783‐792.
Kawaguchi T, Shima T, Mizuno M, Mitsumoto Y, Umemura A, Kanbara Y, et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS One 2018;13:e0185490.
Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway IB, et al. GWAS and enrichment analyses of non‐alcoholic fatty liver disease identify new trait‐associated genes and pathways across eMERGE Network. BMC Med 2019;17:135.
Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg‐Hansen A, et al. Exome‐wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46:352‐356.
Krawczyk M, Liebe R, Lammert F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond. Gastroenterology 2020;158:1865‐1880.e1861.
Emdin CA, Haas ME, Khera AV, Aragam K, Chaffin M, Klarin D, et al. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet 2020;16:e1008629.
Palmer ND, Musani SK, Yerges‐Armstrong LM, Feitosa MF, Bielak LF, Hernaez R, et al. Characterization of European ancestry nonalcoholic fatty liver disease‐associated variants in individuals of African and Hispanic descent. Hepatology 2013;58:966‐975.
Wagenknecht LE, Palmer ND, Bowden DW, Rotter JI, Norris JM, Ziegler J, et al. Association of PNPLA3 with non‐alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int 2011;31:412‐416.
Vespasiani‐Gentilucci U, Gallo P, Dell'Unto C, Volpentesta M, Antonelli‐Incalzi R, Picardi A. Promoting genetics in non‐alcoholic fatty liver disease: combined risk score through polymorphisms and clinical variables. World J Gastroenterol 2018;24:4835‐4845.
Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature 2016;538:161‐164.
Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature 2011;475:163‐165.
Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, et al. Human demographic history impacts genetic risk prediction across diverse populations. Am J Hum Genet 2017;100:635‐649.
Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M. Genome‐wide association studies in diverse populations. Nat Rev Genet 2010;11:356‐366.
Kolonel LN, Henderson BE, Hankin JH, Nomura AMY, Wilkens LR, Pike MC, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000;151:346‐357.
Setiawan VW, Virnig BA, Porcel J, Henderson BE, Le Marchand L, Wilkens LR, et al. Linking data from the Multiethnic Cohort Study to Medicare data: linkage results and application to chronic disease research. Am J Epidemiol 2015;181:917‐919.
Noureddin M, Zelber‐Sagi S, Wilkens LR, Porcel J, Boushey CJ, Le Marchand L, et al. Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: the multiethnic cohort. Hepatology 2020;71:1940‐1952.
Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, et al. Genome‐wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010;139:1567‐1576.
Kitamoto A, Kitamoto T, Nakamura T, Ogawa Y, Yoneda M, Hyogo H, et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 2014;61:683‐689.
Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol 2020;72:1196‐1209.
Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness. Genet Epidemiol 2015;39:276‐293.
He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010;285:6706‐6715.
BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A 2019;116:9521‐9526.
Park SL, Li Y, Sheng X, Hom V, Xia L, Zhao K, et al. Genome‐wide association study of liver fat: the multiethnic cohort adiposity phenotype study. Hepatol Commun 2020;4:1112‐1123.
Sookoian S, Castaño GO, Scian R, Mallardi P, Fernández Gianotti T, Burgueño AL, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015;61:515‐525.
Agius L. Hormonal and metabolite regulation of hepatic glucokinase. Annu Rev Nutr 2016;36:389‐415.
Abul‐Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein‐truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018;378:1096‐1106.
Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, et al. A genome‐wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol‐related cirrhosis. Nat Genet 2015;47:1443‐1448.
Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, et al. The MBOAT7‐TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 2016;150:1219‐1230.e1216.
León‐Mimila P, Vega‐Badillo J, Gutiérrez‐Vidal R, Villamil‐Ramírez H, Villareal‐Molina T, Larrieta‐Carrasco E, et al. A genetic risk score is associated with hepatic triglyceride content and non‐alcoholic steatohepatitis in Mexicans with morbid obesity. Exp Mol Pathol 2015;98:178‐183.
Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D’Erasmo L, Polimeni L, et al. Evaluation of polygenic determinants of non‐alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy. Sci Rep 2018;8:3702.
Gellert‐Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg‐Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 2020;72:845‐856.
Vespasiani‐Gentilucci U, Dell’Unto C, De Vincentis A, Baiocchini A, Delle Monache M, Cecere R, et al. Combining genetic variants to improve risk prediction for NAFLD and its progression to cirrhosis: a proof of concept study. Can J Gastroenterol Hepatol 2018;2018:7564835.
Koo BK, Joo SK, Kim D, Bae JM, Park JH, Kim JH, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non‐alcoholic fatty liver disease. J Gastroenterol Hepatol 2018;33:1277‐1285.